SG11201903697WA - Liver organoid compositions and methods of making and using same - Google Patents

Liver organoid compositions and methods of making and using same

Info

Publication number
SG11201903697WA
SG11201903697WA SG11201903697WA SG11201903697WA SG11201903697WA SG 11201903697W A SG11201903697W A SG 11201903697WA SG 11201903697W A SG11201903697W A SG 11201903697WA SG 11201903697W A SG11201903697W A SG 11201903697WA SG 11201903697W A SG11201903697W A SG 11201903697WA
Authority
SG
Singapore
Prior art keywords
cincinnati
international
liver
burnett
avenue
Prior art date
Application number
SG11201903697WA
Other languages
English (en)
Inventor
Takanori Takebe
Tadahiro Shinozawa
Masaki Kimura
Hiroyuki Koike
Original Assignee
Childrens Hospital Med Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Med Ct filed Critical Childrens Hospital Med Ct
Publication of SG11201903697WA publication Critical patent/SG11201903697WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0671—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
SG11201903697WA 2016-11-04 2017-11-03 Liver organoid compositions and methods of making and using same SG11201903697WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662417371P 2016-11-04 2016-11-04
US201762517414P 2017-06-09 2017-06-09
PCT/US2017/059845 WO2018085615A1 (en) 2016-11-04 2017-11-03 Liver organoid compositions and methods of making and using same

Publications (1)

Publication Number Publication Date
SG11201903697WA true SG11201903697WA (en) 2019-05-30

Family

ID=62076362

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202104575WA SG10202104575WA (en) 2016-11-04 2017-11-03 Liver organoid compositions and methods of making and using same
SG11201903697WA SG11201903697WA (en) 2016-11-04 2017-11-03 Liver organoid compositions and methods of making and using same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202104575WA SG10202104575WA (en) 2016-11-04 2017-11-03 Liver organoid compositions and methods of making and using same

Country Status (11)

Country Link
US (4) US20200056157A1 (ja)
EP (3) EP3534919A4 (ja)
JP (3) JP7244418B2 (ja)
KR (2) KR102546194B1 (ja)
CN (3) CN117229994A (ja)
AU (2) AU2017353982B2 (ja)
CA (2) CA3041714A1 (ja)
IL (1) IL266398A (ja)
NZ (1) NZ753051A (ja)
SG (2) SG10202104575WA (ja)
WO (3) WO2018085615A1 (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
WO2015183920A2 (en) 2014-05-28 2015-12-03 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
WO2016061464A1 (en) 2014-10-17 2016-04-21 Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intetine using pluripotent stem cells and methods of making and using same
CN116790476A (zh) 2016-05-05 2023-09-22 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
WO2018106628A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
EP3635095A4 (en) * 2017-06-09 2021-12-01 Children's Hospital Medical Center LIVER ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF
US20210254012A1 (en) * 2018-06-09 2021-08-19 Arizona Board Of Regents On Behalf Of Arizona State University Next generation designer liver organoids and their methods of preparation and use
SG11202102431YA (en) * 2018-09-12 2021-04-29 Childrens Hospital Med Ct Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
AU2019351022A1 (en) * 2018-09-27 2021-04-15 Children's Hospital Medical Center Liver support system comprising liver organoids and methods of making and using same
EP3950931A4 (en) 2019-03-29 2022-11-30 Nagasaki University CULTIVATED TISSUE AND PROCESS OF PRODUCTION
WO2020243613A1 (en) * 2019-05-31 2020-12-03 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
JP7039045B2 (ja) * 2019-08-26 2022-03-22 株式会社フェニックスバイオ ヒト脂肪肝モデル細胞
JP2023516484A (ja) 2020-03-11 2023-04-19 ビット バイオ リミテッド 肝細胞作製方法
CN113717850A (zh) * 2020-05-26 2021-11-30 中国科学院大连化学物理研究所 一种基于三维类肝芯片的非酒精性脂肪肝体外模型建立方法
WO2021243526A1 (zh) * 2020-06-01 2021-12-09 苏州大学附属儿童医院 新生儿肠外营养相关性肝病特异性标志物lncRNA的应用
WO2021262676A1 (en) * 2020-06-23 2021-12-30 Children's Hospital Medical Center Model for insulin resistance
EP4332215A1 (en) * 2021-04-28 2024-03-06 National University Corporation Tokyo Medical and Dental University Method for producing cells
WO2022236144A1 (en) 2021-05-06 2022-11-10 Massachusetts Institute Of Technology Ex vivo tissue explant and graft platform and uses thereof
CN113430890A (zh) * 2021-07-01 2021-09-24 驻马店市华中公路设计有限公司 用于旧沥青路面改造的永久性复合式路面结构及施工装置
CN115125187B (zh) * 2022-06-14 2023-04-07 创芯国际生物科技(广州)有限公司 一种子宫内膜炎症的类器官体外模型及其建立方法和应用
CN115386535B (zh) * 2022-10-26 2023-02-03 天津外泌体科技有限公司 多谱系肝类器官模型及基于该模型的药物肝毒评价方法
CN115418386B (zh) * 2022-11-03 2023-03-24 成都诺医德医学检验实验室有限公司 一种基于皮肤类器官的损伤愈合评价方法及模型和应用
WO2024185901A1 (ja) * 2023-03-09 2024-09-12 国立大学法人 東京医科歯科大学 脂肪性肝疾患を処置することに用いるための組成物
WO2024206911A2 (en) 2023-03-30 2024-10-03 Children's Hospital Medical Center Clinical-grade organoids

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003050249A2 (en) 2001-12-07 2003-06-19 Geron Corporation Islet cells from human embryonic stem cells
CN103898045B (zh) 2003-12-23 2019-02-01 维亚希特公司 定形内胚层
ES2523591T3 (es) 2006-06-27 2014-11-27 Intercept Pharmaceuticals Inc. Derivados de ácidos biliares como ligandos de FXR para la prevención o el tratamiento de enfermedades o estados mediados por FXR
DE602007012293D1 (ja) * 2006-12-08 2011-03-10 Du Pont
EP2412800A1 (en) * 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
EP2393917B1 (en) 2009-02-03 2016-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells.
WO2010094694A1 (en) 2009-02-23 2010-08-26 F. Hoffmann-La Roche Ag Assays to predict cardiotoxicity
RU2011139643A (ru) 2009-03-17 2013-04-27 Акскан Фарма, Инк. Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты
EP2443230B1 (en) * 2009-06-18 2017-07-26 Takara Bio Europe AB 3D CULTURING SYSTEMS FOR GROWTH AND DIFFERENTIATION OF HUMAN PLURIPOTENT STEM (hPS) CELLS
CN101696396A (zh) * 2009-10-27 2010-04-21 中国人民解放军军事医学科学院卫生学环境医学研究所 乙型肝炎病毒体外感染模型的构建方法及应用
WO2011066369A2 (en) * 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to raise albumin and/or lower crp
JP5897543B2 (ja) * 2010-03-22 2016-03-30 セルアーティス アーベー Ｗｎｔシグナル経路の調節による多能性細胞から肝細胞様細胞への分化誘導と成熟
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US20120291096A1 (en) * 2011-05-12 2012-11-15 Nokia Corporation Method and apparatus for secure signing and utilization of distributed computations
SI3336097T1 (sl) 2012-06-19 2021-07-30 Intercept Pharmaceuticals, Inc. Priprava nekristalinične oblike obetiholne kisline
US20160237400A1 (en) * 2013-03-15 2016-08-18 The Jackson Laboratory Isolation of non-embryonic stem cells and uses thereof
US20160245653A1 (en) 2013-04-30 2016-08-25 Sangtae Park Cylindrical resonator gyroscope
JP6455934B2 (ja) 2013-07-23 2019-01-23 公立大学法人横浜市立大学 生物学的組織に血管系を付与する方法
RU2020119611A (ru) 2014-03-21 2020-06-29 Тобира Терапьютикс, Инк. Сенекривирок для лечения фиброза
MX369921B (es) 2014-04-11 2019-11-26 Cymabay Therapeutics Inc Tratamiento de la hgna y ehna.
WO2015183920A2 (en) * 2014-05-28 2015-12-03 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
CA2950470A1 (en) 2014-06-06 2015-12-10 Vrije Universiteit Brussel Human hepatic 3d co-culture model and uses thereof
IL282156B (en) 2014-07-29 2022-07-01 Shenzhen Hightide Biopharmaceutical Ltd Salts of berberic acid, salts of ursodeoxycholic acid and their combinations, methods for their preparation and their uses
AU2015314830B2 (en) 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
SG11201701844YA (en) * 2014-10-08 2017-04-27 Agency Science Tech & Res Methods of differentiating stem cells into liver cell lineages
CN104387451B (zh) * 2014-11-07 2020-12-18 浙江海洋学院 一种对非酒精性脂肪肝病细胞模型具有修复作用的文蛤酶解寡肽及其制备方法
CN107208054B (zh) * 2014-11-26 2021-09-17 艾克塞利瑞提德生物技术公司 诱导的肝细胞及其用途
EA201892625A1 (ru) 2015-01-09 2019-07-31 Джилид Аполло, Ллс КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ
US20160256672A1 (en) * 2015-02-10 2016-09-08 Cedars-Sinai Medical Center Induced pluripotent stem cell-derived hepatocyte based bioartificial liver device
CN105985395A (zh) 2015-02-13 2016-10-05 江苏奥赛康药业股份有限公司 一种奥贝胆酸化合物及含有该化合物的药物组合物
SG10202103552XA (en) 2015-03-09 2021-05-28 Intekrin Therapeutics Inc Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
KR20170132879A (ko) * 2015-04-07 2017-12-04 인터셉트 파마슈티컬즈, 인크. 조합 요법을 위한 약제학적 조성물
US10557124B2 (en) * 2015-04-22 2020-02-11 The Regents Of The University Of Michigan Compositions and methods for obtaining stem cell derived lung tissue, and related uses thereof
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
BR112017028414B1 (pt) 2015-06-30 2021-09-08 Basf Agro B.V. Arnhem Método de controle de pragas
CN110582564A (zh) * 2015-09-15 2019-12-17 新加坡科技研究局 从人类多能干细胞衍生肝类器官
MX2018003179A (es) 2015-09-16 2018-08-21 Tobira Therapeutics Inc Terapia de combinación con cenicriviroc para el tratamiento de fibrosis.
US10801068B2 (en) 2015-10-16 2020-10-13 The Trustees Of Columbia University In The City Of New York JAG1 expression predicts therapeutic response in NASH
CA3000016A1 (en) 2015-11-06 2017-05-11 Gemphire Therapeutics Inc. Gemcabene combinations for the treatment of cardiovascular disease
EP3426766B1 (en) * 2016-03-08 2022-12-28 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Method for continuous biosensing
EP3228306A1 (en) 2016-04-04 2017-10-11 ratiopharm GmbH Complex compound comprising obeticholic acid and cyclodextrin and pharmaceutical formulation comprising the complex compound
WO2017184586A1 (en) 2016-04-18 2017-10-26 The Trustees Of Columbia University In The City Of New York Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash)
AU2017253228B2 (en) 2016-04-22 2020-04-09 Taiwanj Pharmaceuticals Co., Ltd. Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease
EP3635095A4 (en) * 2017-06-09 2021-12-01 Children's Hospital Medical Center LIVER ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF

Also Published As

Publication number Publication date
KR102546194B1 (ko) 2023-06-21
CN110382012A (zh) 2019-10-25
JP2023085289A (ja) 2023-06-20
JP7244418B2 (ja) 2023-03-22
CA3041714A1 (en) 2018-05-11
KR20230093079A (ko) 2023-06-26
WO2018085622A1 (en) 2018-05-11
CA3041712A1 (en) 2018-05-11
AU2021212060A1 (en) 2021-08-26
CN110381967A (zh) 2019-10-25
JP2022119862A (ja) 2022-08-17
US20200056157A1 (en) 2020-02-20
IL266398A (en) 2019-06-30
US20190314387A1 (en) 2019-10-17
KR20190092394A (ko) 2019-08-07
AU2017353982A1 (en) 2019-05-23
EP3534976A4 (en) 2020-09-16
US20210008123A1 (en) 2021-01-14
JP2019533452A (ja) 2019-11-21
JP2019534006A (ja) 2019-11-28
CN110382012B (zh) 2023-08-25
CN117229994A (zh) 2023-12-15
SG10202104575WA (en) 2021-06-29
WO2018085615A1 (en) 2018-05-11
EP3534907A4 (en) 2020-06-24
EP3534919A1 (en) 2019-09-11
WO2018085623A1 (en) 2018-05-11
EP3534976A1 (en) 2019-09-11
JP7078615B2 (ja) 2022-05-31
EP3534919A4 (en) 2020-11-11
NZ753051A (en) 2023-03-31
US10668108B2 (en) 2020-06-02
JP7545186B2 (ja) 2024-09-04
AU2017353982B2 (en) 2021-05-06
US20190298775A1 (en) 2019-10-03
EP3534907A1 (en) 2019-09-11

Similar Documents

Publication Publication Date Title
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201808990QA (en) Compositions for topical application of compounds
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201808125RA (en) Methods for solid tumor treatment
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201900486WA (en) Treatment and prevention of sleep disorders
SG11201809051YA (en) Cell retention device and method
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201805385QA (en) Bromodomain and extra-terminal protein inhibitor combination therapy
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201900361RA (en) Methods of treating prostate cancer
SG11201805170XA (en) Cellular glycosaminoglycan compositions and methods of making and using
SG11201805771XA (en) Systems and methods for preparation of platelets
SG11201900123TA (en) Compositions and methods for treating frontotemporal dementia
SG11201805788WA (en) Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
SG11201906852XA (en) Treatment of diuretic resistance